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Pancreatic and Intestinal Function Post Roux-en-Y
Gastric Bypass Surgery for Obesity
Stephen J. D. O’Keefe, MD, MSc1, Tina Rakitt, MD1, Junhai Ou, MD1, Ihab I. El Hajj, MD, MPH2, Elizabeth Blaney, MD1,
Kishore Vipperla, MD1, Jens-Jules Holst, MD3 and Jens Rehlfeld, MD4
OBJECTIVES: Despite the fact that the most effective treatment for morbid obesity today is gastric bypass surgery, some patients
develop life-threatening nutritional complications associated with their weight loss.
METHODS: Here we examine the influence of the altered anatomy and digestive physiology on pancreatic secretion and fat
absorption. Thirteen post Roux-en-Y gastric bypass (RYGB) patients who had lost4100 lbs in the first year following surgery and
who gave variable histories of gastrointestinal (GI) dysfunction, were selected for study. Food-stimulated pancreatic enzyme
secretion and GI hormone responses were measured during 2 h perfusions of the Roux limb with a standard polymeric liquid
formula diet and polyethylene glycol marker, with collections of secretions from the common channel distal to the anastomosis
and blood testing. Fat absorption was then measured during a 72 h balance study when a normal diet was given containing
~100 g fat/d.
RESULTS: Result showed that all patients had some fat malabsorption, but eight had coefficients of fat absorption o80%,
indicative of steatorrhea. This was associated with significantly lower feed-stimulated secretion rates of trypsin, amylase, and
lipase, and higher plasma peptide-YY concentrations compared with healthy controls. Five steatorrhea patients were subsequently
treated with low quantities of pancreatic enzyme supplements for 3 months, and then retested. The supplements were well
tolerated, and fat absorption improved in four of five patients accompanied by an increase in lipase secretion, but body weight
increased in only three. Postprandial breath hydrogen concentrations were elevated with some improvement following enzyme
supplementation suggesting persistent bacterial overgrowth and decreased colonic fermentation.
CONCLUSIONS: Our investigations revealed a wide spectrum of gastrointestinal abnormalities, including fat malabsorption,
impaired food stimulated pancreatic secretion, ileal brake stimulation, and bacterial overgrowth, in patients following RYGB which
could be attributed to the breakdown of the normally highly orchestrated digestive anatomy and physiology.
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INTRODUCTION
The prevalence of class III obesity (BMI440 kg/m2, or morbid
obesity) has increased nearly 10-fold since the late 1960s and
doubled since the early 1990s,1 now affecting ~35% of the
male and female population.2 As of 2002, an estimated 22% of
US adults had the metabolic syndrome.3 As of 2012, an
estimated 33% of US adults had the metabolic syndrome.4
Between 1996 and 2002, population adjusted rates of weight
loss surgery increased 47-fold,5 with an estimated 220,000
Americans undergoing weight loss procedures in 2008
(American Society for Metabolic and Bariatric Surgery. Fact
sheet: http://www.asbs.org). The most popular technique
today is the Roux-en-Y gastric bypass procedure (RYGB),
which results in an averageweight loss of ~ 95 lbs per year or a
two out of three loss of the excess weight in 2 years.6 Weight
loss occurs for two major reasons: first, the volume of the
stomach is reduced, and second, the duodenum and first part
of the jejunum are bypassed resulting in malabsorption.
However, alteration in GI anatomy results in a wide spectrum
of changes in digestive and metabolic physiology, many of
which can contribute to weight loss as recently reviewed by
Madsbad et al.7
Although most patients tolerate the RYGB procedure
remarkably well, with a leveling off of weight loss close to the
ideal, about 10% over-swing and continue to lose weight or
develop gastrointestinal or metabolic complications. The most
serious GI complications are anastomotic ulceration and
stenosis, intestinal obstruction, internal herniation and volvu-
lus. In the extreme situation this can lead to loss of intestine,
intestinal failure, and the need for home parenteral feeding and
small bowel transplantation—a sadly ironic situation consider-
ing the original problem was a super-efficient digestive
system. Metabolic complications such as acidosis, hepatic
steatosis and liver failure possibly related to disturbance of the
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gut microbiome, can also be life threatening, but are less
common today with the more conservative Roux lengths of
80–100 cm. Finally, it has recently become appreciated that a
wide spectrum of micronutrient deficiencies, including low
blood levels of iron, copper, zinc, selenium, thiamine, folate,
and vitamins B12 and D, which are not usually monitored, are
common and may contribute to impaired quality of life.8
Knowing that the physiology of digestion and absorption is
highly integrated and orchestrated by neurohormonal
mechanisms, we are concerned that the alteration of the
normal anatomy could have profound effects on the normally
highly integrated process of food-induced pancreatic stimula-
tion and secretion.9 The bypass removes the chief “intestinal
phase” of pancreatic secretion mediated by food entering the
duodenum and instead produces a state of permanent ileal
brake stimulation as larger quantities of undigested food
particles now enter the ileum. This results in the secretion of a
number of peptides such as glucagon-like peptides 1 and 2,
and peptide YY, which suppress pancreatic secretion,10,11
thereby potentially exacerbating maldigestion and absorption.
The aim of the present study was to measure the pancreatic
secretory response to feeding, in concert with food absorption in
a select group of post-bypass patients referred to the University
of Pittsburgh Medical Center (UPMC) Gastroenterology (GI)
Division or the hospital Nutritional Support Service (NSS) for
gastrointestinal or nutritional problems of variable severity.
Second, we investigated whether patients who were shown to
have high rates of fat malabsorption, i.e.,420%,would benefit a
3-month course of pancreatic enzyme supplements.
METHODS
Patients. To date no studies have attempted to measure the
effects of Roux-en-Y gastric bypass surgery (RYGB) on
pancreatic secretion and fat absorption simultaneously. We
therefore purposely selected a spectrum of patients, ranging
from those who had successfully lost weight, had no major
gastrointestinal symptoms, and did not exhibit micronutrient
deficiencies, to those who had lost excessive weight and
suffered from intermittent episodes of severe micronutrient
deficiencies. Patients were selected from those with bypass
referred to the GI or NSS hospital services. All had to satisfy
the following Inclusion criteria: Adult patients with a history
of RYGB, who gave a history of significant weight loss,
intermittent micronutrient deficiencies, or diarrhea, were
eligible if they had a history of morbid obesity, BMI 440 kg/
m2 before surgery, experienced weight loss of430%, or 100
lbs in 1st year following bypass surgery, and were able to
consume normal requirement levels of food. Exclusion
criteria included (1) any cause of chronic pancreatic
dysfunction, such as chronic pancreatitis as evidenced by
history, pancreatic imaging (CT or MRP scanning or ERCP),
alcohol abuse (43 units of alcohol/day), (2) intestinal
resection other than RYGB, (3) impaired mucosa function
due to the presence of chronic inflammatory bowel or chronic
small intestinal mucosal disease confirmed by radiology and
biopsy, and (4) unstable fluid and electrolyte balance and/or
cardio-respiratory status (BP diastolic 4100 mm Hg, systolic
4200 oro80 mm Hg, ambient pO2o90%). Recruitment was
continued until five patients with coefficients of fat absorp-
tiono80%, the commonly used cut-off level for the definition
of steatorrhea, had completed the 3-month pancreatic
enzyme supplementation study. Results were evaluated by
comparison to our previously published results from seven
normal healthy volunteers given the same form of enteral
feeding under similar conditions.12 Informed signed consent
was obtained from all participants, after the final protocol had
been reviewed and approved by the University of Pittsburgh
Institutional Review Board.
Study design. The study was divided into two phases. All
patients satisfying the above criteria entered Phase 1, which
consisted of the measurement of food-stimulated pancreatic
secretion and 72 h fat absorption. Those found to have a
coefficient of fat absorptiono80%, were invited to join Phase
2, where they were given pancreatic enzyme supplementa-
tion for 3 months and then restudied in the same way to
assess whether pancreatic enzyme supplementation can
improve digestive function, control gastrointestinal symp-
toms, and maintain nutritional status.
Phase I: measurement of the pancreatic secretory response
to feeding. All subjects were admitted following an overnight
fast to the University of Pittsburgh Clinical and Translational
Research Center (CTRC) for the measurement of pancreatic
enzyme secretion, followed by a 72-h fat absorption study
while on a standard 100 g fat diet. The pancreatic secretory
response to enteral feeding was measured as previously
described in normal healthy controls following the placement
of a double-lumen feeding tube system by transnasal
endoscopy and fluoroscopic imaging with subsequent marker
perfusion of the proximal duodenum followed by aspiration of
duodenal contents 20 cm downstream.13 In gastric bypass
patients, this method had to be modified because of their
altered gastrointestinal anatomy (Figure 1). In order to ensure
full examination of the upper GI tract and Roux limb, an
enteroscope was passed down to enter the “common limb”
just distal to the Roux anastomosis.
First, the distance from the incisors to the gastroenterost-
omy was measured (x). Then the enteroscope was passed
down to the Roux anastomosis and the distance again
recorded (y). The length of the Roux limb was then calculated
from y–x. The endoscope tip was then advanced distally down
the common channel as far as possible and then a flexible
ERCP-type guide wire (e.g., JAG-wire, Wilson-Cook, NC,
USA) was passed through the endoscope and advanced
under fluoroscopy to at least 30 cm past the Roux anasto-
mosis. The enteroscope was carefully withdrawn, feeding the
guide wire through at the same time to maintain distal position.
A double lumen feeding tube system (“Kangaroo- Dobbhoff”
system, Covidien-Kendall-Tyco Products, MA, USA), which
has a 97 cm outer 16 French tube (“G-tube”, used usually for
gastroduodenal decompression) and an inner, adjustable,
170 cm 9 French jejunal tube (J-tube) was then passed over
the per-oral guide wire with the J-tube in the withdrawn
position. Under fluoroscopy, theG-tubewas passed as far past
the gastroenterostomy as possible, i.e., ~ 95 cm (easy
because the remaining stomach is minimal). The J-tube was
then fed all the way down the Roux limb over the guide wire to
~ 20 cm past the Roux anastomosis in the common channel.
Maldigestion after Gastric Bypass Surgery
O’Keefe et al.
2
Clinical and Translational Gastroenterology
Finally, a 10 French “duotube” (CORPAK MedSystems, Inc.,
Buffalo Grove, IL, USA) was fed transnasally into a position
below the gastroenterostomy. The patient was then trans-
ferred back to the CTRC for the 2-h pancreatic secretion test.
To do this, feeding with a balanced polymeric formula diet
(“Ensure”, Ross-Abbott Labs, Chicago, IL, USA) was com-
menced through the duotube at a constant rate for 2 h to
provide normal nutritional requirements, i.e., 1.5 g protein and
40 kcal energy/kg ideal body weight/day. At the same time
perfusion of the segment containing the Roux anastomosis
was commenced through the G-tube with normal saline
containing polyethylene glycol (PEG 3350 Da; 5 g/l) molecular
weight marker at 300 ml/h, and the common post-Roux
anastomosis channel tube was placed on low-intermittent
suction. Aspirates were separated 15-min collections through-
out the 2 h and divided into 5 ml aliquots. One sample was
used to measure trypsin immediately in the lab, and the other
treated with aprotinin protease inhibitor before being stored
frozen at −80 °C for the later measurement of amylase, lipase
and PEG concentrations, as previously described.13 While the
anatomical position was different between patients and
healthy controls, we are investigating digestion and absorption
at the place where food and enzymes meet in both healthy
volunteers and patients.
Calculations: secretion rates were calculated from the
equation:
Pancreat ic enzyme secret ion U=hð Þ
¼ activ u=mlð Þ ´PEGin g=lð Þ ´ IR ml=hð Þ½ CPEGout g=lð Þ
where activ is the enzyme activity in the aspirate, PEGin is the
concentration of PEG in the perfusate, PEGout is the PEG
concentration in the intestinal aspirate and IR is the intestinal
perfusion rate.13
Investigation of the ileal brake responses to feeding. During
the feeding-stimulated pancreatic secretion study, venous
blood samples were taken at 0, 60, and 120 min for
measurement of plasma gastrin, cholecystokinin (CCK),
peptide YY (PYY), and glucagon like peptide (GLP)-)-1
responses to feeding, as before.12
Measurement of 72 h Fat Absorption. Following completion
of the secretion study, subjects remained in the CTRC and
were given ad lib meals until midnight, then fasted until
0800 h, when they were asked to empty their bladders and
bowels so that 72 h collections of urines and stools could be
commenced. Over this period, they were given their usual
diet, prepared individually by the CTRC dietitian, adjusted if
necessary to contain ~ 100 g fat. Actual consumption rates
were calculated by subsequent analysis of the types and
quantities of foods consumed using a conventional computer
software package. The urine and fecal collections were
divided into three consecutive 24 h periods ending at 0800 h,
when, again, patients were asked to force themselves to
empty their bowels and bladders, but this time the outputs
were included with the collections, as previously.14,15 Total
72 h stool collections were weighed and then compounded
into a single collection and sent to the hospital lab for routine
Figure 1 Positioning of the perfusion-aspiration tubes, and feeding tube for the measurement of pancreatic exocrine secretion (a) left panel. This was achieved by
enteroscopy (b) middle photograph showing the Roux anastomosis, and fluoroscopy (c) radiograph upper right image and guide wire deployment. Blue arrows connect shared
features of the three images.
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analysis of total fat content. To assess the effect of
supplements on carbohydrate malabsorption and subse-
quent salvage by the colonic microbiota, we also measured
breath hydrogen responses to the main midday meal at
half-hourly intervals for 6 h during the 72 h fat absorption
studies.16
Calculations
Coefficient of fat absorption CFAð Þ
¼ Fatdiet–Fatstoolð Þ ´ 100%
Fatdiet
Definition of clinically significant fat malabsorption. An
abnormal CFA is o95%.17 However, for the purposes of this
study, only patients with a CFA ofo80%, which is consistent
with clinically significant fat malabsorption and steatorrhea,
were eligible for Phase 2 three month pancreatic enzyme
supplementation study.
Phase II: three month pancreatic enzyme supplementation
study. On discharge from the CTRC, patients returned
home to await the results of the fat absorption study. Patients
shown to have a coefficient of fat absorption o80% were
entered into the pancreatic enzyme supplementation study
and given one month supplies with instructions to take 4
capsules of supplements with each meal (10,000 USP units
of lipase per capsule), and 2 with snacks, to a maximum of 16
capsules per day, for 3 months to assess tolerance, clinical
signs and weight change. This was the manufacturer’s
recommended starting dose for patients with pancreatic
insufficiency. It provides, however, a lower quantity of lipase
than that estimated to be secreted by the normal pancreas
following a normal meal of 1,680,000 USP units, and is also
lower than the lowest “normal” lipase output (2 SD below the
mean) of 900,000 USP units per meal.18 As Di Magno’s
classical studies suggested that only 10% of “normal”
secretion was needed to prevent steatorrhea,19 the absolute
minimum dose to prevent fat malasorption due to pancreatic
insufficiency would have been 90,000 USP units per meal,
which is higher than the 40,000 units per meal we gave
during the 3 month intervention. This conservative level of
dosing was selected as the pathophysiology of gastric
bypass malabsorption is quite different from that of chronic
pancreatic insufficiency—on which the above requirement
estimates were made—and we preferred to err on the low
side for reasons of safety. The pancreatic enzyme supple-
ment consisted of the currently commercially marketed
product “Creon” (AbbVie, North Chicago, IL) which is an
extract from porcine pancreas glands containing amylolytic,
lipolytic and proteolytic activity, formulated as enteric-coated
minimicrospheres. Each capsule delivers 10,000 USP units
of lipase. The drug was manufactured by SPL Ltd, and
supplied by Solvay under product investigational new drug
(IND) 47546. As the use of supplements for gastric bypass
patients was not one of the indications, we obtained our own
IND for the study (76586). It should be noted that the
currently available capsule that contains 12,000 USP units is
considered equivalent, because of the practice of “overfilling”
used with the older product. Chronic medications remained
the same before and after supplementation. Finally, at the
end of the 3 months, the pancreatic secretion and fat
absorption investigations were repeated whilst receiving
enzyme supplementation.
Progress was followed weekly by telephone, and by
monthly visits to the Digestive Disease Clinic. At the end of
this period, they were readmitted to the CTRC for repeat
testing (i.e., as for Phase I) as above, but this time they were
given enzyme supplementation 3 h before the pan-
creatic secretion study (4 capsules). During the 72 h fat
absorption study, meals and snacks were supplemented
with pancreatic enzymes as described above. Finally, breath
hydrogen responses to the midday meal were again followed
for 6 h.
Sample analysis
Pancreatic enzymes. Duodenal juice samples were prepared
as previously for trypsin, amylase, and lipase activity
measurement.12 Trypsin was measured immediately in fresh
samples, while amylase and lipase were measured in frozen
samples preserved with trypsin inhibitor, aprotonin. The
principle of the trypsin assay is based on the hydrolysis of
N-benzoyl-L-arginine ethyl ester (BAEE) to N-benzoyl-L
arginine (BA) and ethanol by trypsin in fresh intestinal
secretions. Lipase and amylase were measured by simulta-
neous microplate technique in the UPMC Pathology labora-
tory using a Bio-Tek SynergyHT multi-detection microplate
reader. The principle of the quantitation is the same, based
on the ability of pancreatic enzymes within the juice samples
to digest starch and triglyceride to produce colorimetric
changes in metabolite complexes.
Gut peptides. Analysis was performed as we have described
in healthy volunteers,12 principally by radioimmunoassay in
frozen plasma samples. Gastrin, CCK, GLP-1, and PYY were
measured in Dr Holst’s and Dr Rehlfeld’s lab in Copenhagen,
Denmark.
Statistical analysis. Results are presented as medians
(range) for descriptive demographics and by group means
(s.e.m.). Results in patients were evaluated by comparison to
healthy volunteers, termed “controls” using StatView software
to investigate our specific aims and explore our hypothesis
that surgical modification of the GI tract could lead to
maldigestion and malabsorption that may be reversed by
pancreatic enzyme supplementation. The significance of the
observed differences in group mean values was determined
by Student’s t-testing for unpaired data (e.g., patients vs.
controls) if the data were normally distributed, or by Mann–
Whitney rank sum test if not. Probabilities of o0.05 were
accepted as significant.
RESULTS
Baseline demographic characteristics. Fifteen subjects
were enrolled, but only 13 met criteria for study and were
included in this analysis. Pre-bypass BMIs (body mass index)
varied from 43 to 67 Kg/m2 (Table 1). Time since bypass
surgery ranged between 3 and 11 years. Eight had had
cholecystectomies before bypass, and four hysterectomies.
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Five were smokers, four had given up. Their initial weight loss
varied from 45 to 138 kg in the first year. Five had been
treated for anastomotic ulcers and three for internal hernias
with the release of adhesions, without intestinal resection.
After the first year, three regained and four continued to lose
weight, such that at the time of enrollment in the study, one
was underweight (BMI 16.4 Kg/m2) and one remained obese
(BMI 430).
Most patients expressed complex disease, with multiple
complaints as summarized in Table 2, many of which pre-
existed prior to bypass surgery. All gave a history of having
intermittent bowel dysfunction for which they had sought help
from gastroenterologists, six with chronic diarrhea. This was
mild in four, but severe in two (#11 and #14). Patient #11 was
noteworthy in that his stools were watery and contained
undigested material and free oil (for detailed history and
outcome, see below). Two had constipation associated with
chronic abdominal pain, attributed to previous surgery, and
narcotic use. Five suffered from chronic abdominal pain
needing intermittent narcotics and six had chronic depression
and/or anxiety.
Although all patients were shown to have elevated stool
fats (i.e., 45 g/d), we had to enroll 13 patients before we
could complete five subjects with CFA o80% through
phase 2. It should be noted that 8 of the 13 were shown to
have CFAs o80%, but three either declined further study
or dropped out of the Phase 2 enzyme supplementation
study. One (#14), a 36-year-old woman with a past history of
liver failure attributed to non-alcoholic steatohepatis with
multiple micronutrient deficiencies had fat absorption o50%.
She was possibly the most chronically disabled of the patients
studied, having recently been readmitted to the ICU with
weight loss, mental status changes (sleepiness, confusion)
associated with a desquamative dermatitis principally affect-
ing the limbs and corners of the mouth. Blood tests revealed a
wide range of vitamin and mineral deficiencies, including
potassium, magnesium, zinc, iron, thiamine, nicotinamide,
ascorbic acid, folate, B12, and vitamin D. A diagnosis of
acrodermatitis enteropathica had been supported by skin
biopsy (Figure 2).
Table 1 Demographic details of the post RYGB patients included in the study
Variable: median (range) Study population (n=13) Healthy volunteers (n= 7)
Age: years 49 (22–58) 26 (22–45)
Sex, n
Female 12 4
Male 1 3
Time since surgery, years 6.5 (3–10.75)
Pre-op weight, Kg 131.1 (111.1–190.5)
Pre-op BMI, Kg/m2 48.8 (43.4–67.2)
Weight loss in first year, Kg 52.3 (45.5–138.6)
Weight on enrollment, Kg 68 (49–114) 80 (53–103)
BMI on enrollment, Kg/m2 25.5 (16.9–42.5) 24.4 (18.6–32.0)
Numeric results given as group median and range in brackets
.
Table 2 Reported medical problems in the RYGB study cohort
PRE-BYPASS POST-BYPASS
Gastroesophageal Reflux 7 3
Asthma 3 4
Obstructive Sleep Dyspnoea 6 1
Anxiety Depression 4 7
Osteoarthritis 5 5
Metabolic Syndrome 5 2
Chronic Abdominal Pain 0 5
Diarrhea 0 6
Figure 2 Desqamative skin lesions in patient #14. Biopsy confirmed a diagnosis
of acrodermatitis enteropathica, associated with a wide range of vitamin and mineral
deficiencies, including low plasma potassium, magnesium, zinc, iron, thiamine,
nicotinamide, ascorbic acid, folate, B12, and vitamin D.
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She recovered quickly with a short course of parenteral
nutrition, and was weaned successfully back on to a normal
balanced diet supplemented with the micronutrients she had
been deficient in, and discharged home. As she now satisfied
the inclusion criteria, she was entered into Phase 1 of the
study. Significant fat malabsorption was confirmed (stool fat
40 g/d), and she was commenced on pancreatic enzyme
supplementation. Unfortunately, she was non-compliant and
was unable to tolerate the supplements during her recurrent
attacks of abdominal pain and chose not to return after
3 months for repeat testing. A further patient, #1, with a history
of intermittent diarrhea, wasmistakenly given 173 g fat per day
during the baseline study, making it difficult to compare her
responses to the other supplemented patients. The third
patient, #4, declined continuation in the study for personal
reasons.
Food-stimulated pancreatic secretion and GI peptide
responses. We were able to aspirate sufficient serial secre-
tions from the common channel in all but two patients, namely
# 5 and #15, to measure secretion rates. In #5 the tube was
partially dislodged in transport back to the research center
and couldn’t be repositioned. In #15, good position was
achieved for the aspiration tube despite the Roux limb being
exceptionally long (~200 cm). However, on both before and
after enzyme supplement testing, no juice could be aspirated.
This could be interpreted as zero secretion, but it was likely
technical, and so we excluded this patient from the analysis.
In the remaining patients, trypsin (P= 0.005 unpaired t test),
amylase (P=0.008) and lipase (Po0.0001) secretion rates
were significantly lower in patients than controls (Figure 3a).
On the other hand, measurements of peptide-YY concen-
trations were higher (P=0.007), while plasma CCK and
GLP-1 were not (Figure 3b). The magnitude of the decrease
in lipase was greatest for unexplained reasons. There was a
significant (Po0.0001) negative correlation between lipase
(r2 0.618, P= 0.0002) and trypsin (r2 0.318, P=0.02)
pancreatic secretory responses and the plasma peptide-YY
responses to feeding at 120 min (Figure 3c). Fasting PYY
plasma concentrations were also significantly higher in
patients with and without pancreatic enzyme supplementa-
tion (Figure 4).
72 h balance studies. Although we tried to keep each
individual’s fat intake to 100 g/d, dietary analysis (Table 3)
showed that actual intake ranged from 73 to 173 g/d, the
median being 98 g/d. All patients had increased stool fat
quantities, ranging from 11 to 100 g/d. One patient (#11), with
a history of internal hernia, weight loss and diarrhea, was
Figure 3 Illustration (group mean (s.e.m.)) of (a) the significantly lower enteral feed stimulated secretion rates of pancreatic trypsin (P= 0.005), amylase (P= 0.008), and
lipase (Po0.0001, upper panel left) and (b) higher plasma peptide-YY (PYY) levels (Po0.01, left), but not CCK or GLP-1 levels, at each time point in RYGB patients compared to
healthy controls. The lower left panel illustrates the significant negative correlation between trypsin secretion and plasma PYY responses measured at at 120 min into the infusion
(r2 0.618, P= 0.0002,). Lipase units Ku/h, PYY pg/ml.
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remarkable in so far as he appeared to have no significant fat
absorption (i.e., 6%, Table 3).
Sub-analysis of patients with coefficients of fat malab-
sorption o80%. Group mean stool fat quantities were
61± 13 g/d in those with CFA o80% and 23±6 g/d in those
with CFA 480%. No distinguishing factors were identified in
the eight patients (Table 4) with coefficients of fat absorption
less than 80%. For example, current body mass indices
(28±3 vs 26±2 kg/m2, respectively), length of the Roux limb
measured at endoscopy (130±20 vs. 137± 14 cm), time
from surgery (64± 17 vs 81±11 months), weight loss in the
first year (119±8 vs. 144± 24 lbs), GI symptoms, gut peptide
and pancreatic enzyme responses to feeding, and urine
nitrogen losses (7.9±2.8 vs. 9.1± 1.3 g/d) were all similar.
Rates of amylase and lipase secretion were not significantly
lower, and there was no significant correlation between lipase
secretion and fecal fat excretion.
The effects of 3 months of pancreatic enzyme supple-
mentation. The responses to pancreatic enzyme supple-
mentation were variable. In general, the pancreatic enzyme
supplements were well tolerated and stool fat excretion
decreased in 4/5 (Table 3), and the group mean stool fat
excretions decreased from 60.6± 13.4 to 36.6± 7.2 g/d,
P= 0.07. Importantly, in the four who showed increases in
fat absorption, the increases did not achieve the 480% cut
off, indicating the malabsorption was not only caused by
enzyme deficiency-maldigestion. Repeat pancreatic enzyme
secretion testing after 3 months treatment showed a
significant increase in lipase (P= 0.027) but not in trypsin
and amylase secretion, and an increase in plasma PYY
(P= 0.0002), but not in CCK, gastrin or GLP-1 responses
(Table 4).
Body weight increased in three participants and decreased
in two. One patient (#8, Table 4) complained that she
experienced ‘nausea when taking supplements with foods
that did not contain fat’, but body weight remained constant
(1.1 kg loss after 3 months), and another (#2, Table 4)
noted ‘increased hunger and diarrhea’ with the full dose,
and so reduced the dosage to twice a day with meals with
relief of these symptoms without weight loss (gained
1.5 kg). In three patients, stool frequency and consis-
tency improved (#s 2, 8, 15), but in one (#11), frequent watery
stools continued despite a reduction in stool fat from 100 to
53 g/d.
Breath hydrogen responses. Breath hydrogen responses
were remarkably different compared with our previous
Figure 4 Changes in plasma gut peptide responses during the 2 h feed-
stimulated pancreatic secretion study, illustrating the higher basal and food
stimulated PYY concentrations in patients, which became even higher after
pancreatic enzyme supplementation, with no significant change in CCK and GLP-1
levels.
Table 3 Baseline (Phase 1) and post pancreatic enzyme supplementation
(Phase 2) measurements of 72 h fat balance studies
Patient # Phase Stool weight
g/24 h
Stool fat
g/24 h
Diet fat
g/24 h
Coefficient
fat abs %
1 1 754 46 173 73a
2 1 1700 68 79 14a
2 2 820 33b 98 66
3 1 287 11 97 89
4 1 1354 47 73 36a
5 1 553 10 94 89
6 1 694 31 104 70a
6 2 699 26 100 74
7 1 300 11 100 89
8 1 2105 30 94 68a
8 2 1915 53 92 42
9 1 1384 11 100 89
11 1 7557 100 106 6a
11 2 5526 53 100 47
13 1 798 6 98 94
14 1 732 40 80 50a
15 1 1876 74 98 24a
15 2 464 17 100 83
Note 15 subjects were enrolled, and 13 met criteria for study and were included
in this analysis.
aindicates those with coefficients of fat absorptiono80% (steatorrhea).
bestimated from change in stool volume.
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measurements in normal healthy subjects. In health, breath
hydrogen concentrations are low after a meal and only
begin to increase after 4–6 h, when carbohydrate residues
(e.g., fiber) enter the colon and are fermented by the
microbiota.20,21 In sharp contrast, hydrogen concentrations
were persistently high throughout the 6 h postprandial test
indicating persistent activation of the microbiota (Figure 5).
The early increase could be explained by bacterial over-
growth of the upper GI tract or rapid oro-colonic transit,
and the late increase by carbohydrate malabsorption and
increased colonic fermentation.22
Post study follow-up. The four patients (#s 2, 8, 11, 15)
with coefficients of fat absorption o80% and who experi-
enced reductions in diarrhea and/or improvements in fat
absorption with enzyme supplements, were continued on the
supplements off-study following completion of phase 2. All
but one, patient #11, showed continued benefit. Patient 11
was remarkable as he continued to have severe diarrhea,
with further weight loss and electrolyte deficiencies necessi-
tating the intermittent use of parenteral nutrition at home.
Colonoscopy appeared normal and so a capsule endoscopy
was performed which suggested abnormal mucosa in the
distal ileal common channel. A small bowel barium study
supported the concern about ileal disease, showing a 20 cm
stenotic segment. This patient gave a previous history of an
internal small bowel hernia (“whole ileum and jejunum
herniated through the retrojejunal space”) 4 years following
successful bypass and 2 years previously. Laparoscopy
showed evidence of ischemia in the herniated bowel
(“purple”), but decompression resulted in relief of ischemia
(“pink”) and his acute abdominal pain. Because of concern
that the explanation for stenosis and continued diarrhea was
chronic ischemia related to this problem, or other pathology of
the ileum, our intestinal rehabilitation surgeons performed a
laparotomy. Biopsy of the liver confirmed steatohepatis, but
more relevantly they noted that “the terminal ileal loops were
herniated into a huge mesenteric defect at the Roux
anastomosis…”, a finding they considered to unequivocally
explain the patient’s symptoms of intermittent obstruction,
abdominal pain, and diarrhea. Indeed, these symptoms were
relieved by repair of the hernia without the need for intestinal
resection. Furthermore, he gained 10 kg, but 6 months later,
he was admitted with acute pneumonia to the ICU and died
expectantly of severe complicating adult respiratory distress
syndrome.
DISCUSSION
Our study well illustrates the complex changes in digestive
physiology and anatomy induced by Roux-en-Y gastric
bypass surgery (RYGB) for obesity. Fat malabsorption of
variable degrees was universal, confirming the view that
weight loss can at least be partially explained by food
malabsorption related to the shortened functional length
of small intestine. Defining “clinically significant” fat malab-
sorption, or steatorrhea, as a coefficient of fat absorption
o80%, 8 of the 13 fell into this category. Two of the thirteen
gave a documented history of malabsorption measured by
stool fat content, but in the remainder, it was asymptomatic
and unrecognized. In the five patients in our study with
steatorrhea who progressed to the three-month low dose
pancreatic enzyme supplementation study, the effect was
variable, with an increase in fat absorption in four, but an
increase in body weight in only three. In the patient with the
most severe fat malabsorption (#11), enzyme supplementa-
tion reduced stool fat losses 50%, but had little effect on the
patient’s chronic diarrhea and weight loss, which was later
attributed to chronic intestinal ischemia in the common
channel.
We are not aware of previous attempts to measure the
pancreatic secretory responses to feeding in patients with
RYGB.While this was technically challenging, we were able to
recover sufficient post-Roux secretions and use standard
marker correction techniques to assess overall secretory rates
during the 2 h study in all but two patients. Calculated
secretion rates of trypsin, lipase and amylase were well below
those measured in healthy volunteers given the same form of
feeding. It is possible that some of the difference could be due
to technical differences related to the distortion and changed
anatomy, but studies of ours have previously shown that the
endoscopic aspiration of a single intestinal juice sample can
provide information on the function of the pancreas.23
Our measurement of low feed-stimulated pancreatic
enzyme secretion rates is novel and suggests a further
mechanism, i.e., maldigestion, explaining fat malabsorption.
Table 4 Group mean (s.e.m.) changes in pancreatic enzyme secretion and
plasma gut peptide responses to enteral feeding in five patients with coefficients
of fat absorptiono80 following pancreatic enzyme supplementation
Gastric
Bypass (GB)
GB plus
supplements
Trypsin secretion Ku/h 241 (42) 279 (42)
Amylase secretion Ku/h 32 (8) 35 (7)
Lipase secretion Ku/h 35 (7) 191 (91)*
CCK pg/ml 2.2 (0.3) 3.6 (0.9)
Gastrin pg/ml 10.6 (1.7) 9.1 (1.6)
GLP-1 pM 15.1 (1.4) 15.9 (2.1)
PYY pg/ml 97.8 (6.3) 152.6 (14.2)*
*po0.05
Figure 5 Changes in breath hydrogen responses to the midday meal following
3 months of pancreatic enzyme supplementation, showing significant suppress-
ion at multiple time points (*Po0.05) and restoration of the normal biphasic
pattern.
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That this was not the primary cause of malabsorption was
given by our observation that pancreatic enzyme supplements
only increased fat absorption in four of the five treated patients,
and even then did not normalize absorption. However, as
discussed under Methods, the pancreatic enzyme supple-
ments dose we used may well have been insufficient to
reverse the maldigestion and malabsorption, particularly
because all treated patients continued to have high stool fat
excretions, despite the reductions. Further studies are
warranted to determinewhether higher dose supplementation,
or a more dispersible non-enteric coated preparation com-
bined with gastric acid suppression, could increase fat
absorption further. Interestingly, lipase secretion in the five
treated with pancreatic enzyme supplements increased
significantly after the 3-month supplementation. The mechan-
ism is unclear, but it could have been related to improved
protein digestion and absorption resulting in improved
pancreatic enzyme synthesis.24
The gastric bypass procedure has a major effect on
the endocrine control of digestive physiology. Each
segment of the intestine has a series of feedback loops that
control the rate of secretion of digestive juice and migration of
digesta through the absorptive areas. The passage of food into
the upper GI tract stimulates pancreatic secretion to facilitate
rapid digestion and absorption, whereas unabsorbed food
entering the distal bowel inhibits secretion and motility to
suppress fluid losses and prolong nutrient-mucosa contact
time in order to maximize absorption. As shown on Figure 1,
RYGB largely bypasses the gastric and intestinal phases
of pancreatic stimulation and dumps undigested food
into the ileum triggering the release of ileal brake peptides
such as peptide-YY, GLP-I and GLP-2 from neuroendocrine
L-cells in the distal bowel, which are responsible for the
negative feedback, suppressing secretion and motility. The
possibility that the low food-stimulated pancreatic enzyme
secretion rates were related to “ileal brake” stimulation by
malabsorbed nutrients was evidenced by the finding of
significant elevations in peptide-YY (PYY) blood levels in the
presence of normal cholecystokinin (CCK) responses, and the
negative correlations between plasma PYY and pancreatic
trypsin and lipase secretions at baseline. Human gut intuba-
tion studies have shown that the intraileal perfusion of lipids
and amino acids inhibited pancreatic exocrine secretion,10
and further studies have linked the suppression to the
simultaneous release of PYY and glucagon like peptide 1
(GLP-1) from the entero-endocrine L-cells.25 It is unclear
why we failed to see an increase in GLP-1 in the current
study, but the explanation might lie in the duration of study, as
others have also noted increases in PYY but not GLP-1 in
short term human ileal perfusion studies.26 PYY has powerful
antimotility effects on the proximal bowel,11,25 which, together
with GLP-1, may augment the role of the ileal brake in
weight loss due to early satiety, adding a third explanation to
the efficacy of RYGB in weight loss.25,27,28,29 Others have
demonstrated heightened PYY responses to feeding following
RYGB. Chronaiou et al showed that PYY, and GLP-1 area
under the curve responses to a mixed test meal remained
higher at 3, 6, and 12 months in 12 post-RYGB patients
compared with pre-surgery. Jacobson et al showed that
the postprandial response to a mixed meal increased for
C-peptide, GLP-1, GLP-2, PYY, CCK, and glucagon within
2 weeks of bypass surgery.30,31 Finally, pancreatic poly-
peptide, another peptide linked to the ileal brake, provides an
alternative mechanism through its ability to interfere with
cholinergic transmission, which is the chief determinant of
pancreatic stimulation and secretion,32 supporting the con-
clusion that the ileal brake is a highly complex regulatory
system affecting both upper GI motility and pancreatic
secretion.
Another fascinating observation in our study was that PYY
levels were already elevated before feeding in our study
population. We have no explanation for this, as retained food
was not found in the stomach during feeding tube placement
under fasting conditions. Nor can we explain why levels
increased further, at all time points, following three months
of enzyme supplementation. If anything, improved digestion
and absorption should reduce ileal brake stimulation. One
point against the ileal brake theory was our finding of
higher lipase secretion rates accompanied by higher plasma
PYY responses following 3-months of pancreatic enzyme
supplementation.
To the best of our knowledge, there are no publications of
the effect of RYGB on microbial fermentation. Our measure-
ments of increased fasting and fed breath hydrogen excretion
rates suggested a general disturbance of gut function,
possibly explained by small bowel bacterial overgrowth and
increased colonic fermentation of malabsorbed carbohydrate
and protein.22 Dislocation of the digestive anatomy likely
explains this through the lack of bacteriostatic gastric and
biliary secretions in the upper small intestine and the
increased flow of undigested carbohydrate into the colon.
The suppression of breath hydrogen following oral pancreatic
enzyme supplementation supports this suggestion. There is
no easy way of treating small bowel bacterial overgrowth,
as chronic antibiotic therapy has its own problems and can
exacerbate diarrhea.20
The complexity of these changes, combined with the low
“safe” dose of pancreatic enzyme supplements used, most
likely explains our observations of a partial response to
exogenous enzyme supplementation. The complexity might
also explain why fat malabsorption was identified in all RYGB
patients, even in those without symptoms. A further factor
identified in one patient was the presence of distal intestinal
dysfunction in the common “absorption” channel below the
Roux anastomosis due to chronic ischemia due to chronic
subacute volvulus associated with a large internal hernia. Our
own unpublished experience is that this condition is not that
uncommon after bypass surgery and often devastating,
resulting in intestinal gangrene and subsequent intestinal
failure due to short bowel, necessitating home parenteral
nutrition. Some of these patients have deteriorated further with
the development of liver failure, demanding a liver-small
intestine transplant for survival.33 In a recent review of the
Pittsburgh and Cleveland Clinic experience, Abu-Elmagd et al
described the outcomes of 142 post-bariatric surgery patients
who developed intestinal failure. Twenty-three ended up
needing visceral transplants. Nutritional autonomy was
achieved by transplantation in 83%. Twenty-three percent
went on to become obese again, well illustrating the point that
the gut is not the culprit of the initial problem.
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The most recent Cochran review of bariatric surgery
identified 22 usable studies, which included 1,798 patients,
followed up generally for only 1–3 years34—unlike our study
population who were between 3 and 11 years post bypass
surgery. While weight loss was well reported, and some
studies measured glucose and lipid responses and quality of
life, no comparative analyses of specific nutritional outcomes
were evaluable. The reviewers concluded that “……while
there was good evidence for sustained weight loss, adverse
events were poorly reported and follow-up was generally far
too short, i.e., 1 to 2 years, therefore the long term effects of
surgery remain unclear”.
A series of recent studies have highlighted the fact
that while gastric bypass patients can appear to be
doing well, multiple micronutrient abnormalities are often
present, including deficiency of iron, copper, zinc, selenium,
thiamine, folate, and vitamins B 12 and D.8 Unfortu-
nately, these parameters were not closely monitored in our
patients, as the problem was not recognized at the time the
study was designed. The amalgamation of these apparently
“subclinical” deficiencies can be expected to compromise
physical and mental well-being. This might account for the
observation that while RGBYappears to improve quality of life
during the first and second year following surgery—when the
influence of weight loss is predominant—by 4 years, only
general health and functional capacity parameters remained
better.34 The true depth of these micronutrient deficiencies
is likely underestimated, as blood levels commonly do not
reflect cellular deficiency and consequent organ functional
impairment.
Our results add new information on the detrimental effects of
RYGB on the normally highly orchestrated processes of
digestion and absorption. For example, the digestive process
is generally 495% efficient as the secretion of digestive
enzymes by the pancreas occurs in three phases, the
cephalic, the gastric, and the intestinal phases, to ensure
orderly food breakdown, fluid and enzyme secretion, steriliza-
tion and finally thorough mixing of the digesta to maximize
enzyme activity and food hydrolysis to release absorbable
elemental nutrients.35 Bypassing much of the upper GI tract
results in loss of gastric and the intestinal phase of pancreatic
secretion, and dislocation of the inflow of pancreobiliary
secretions into the distal small intestine results in impairment
of mixing of food and enzymes, disturbed neuroendocrine
control, loss of the migrating motor complexes, stasis and
small bowel bacterial overgrowth. Furthermore, the heigh-
tened flow of undigested food particles into the distal bowel
produces chronic stimulation of the ileal brake, which
exacerbates the impairment of gastric, pancreatic, and biliary
secretions.
In conclusion, our study highlights the fact that while
RYGB is remarkably successful in achieving sustained
weight loss and the removal of the metabolic complications
associated with morbid obesity, it unties the functional
anatomy of the human gut and digestive physiology that has
taken millions of years of evolution to achieve. If these
alterations are compounded by additional medical or surgical
complications, a state of intestinal failure can result, culminat-
ing in the loss of essential nutrients and life-threatening
complications. For these reasons, alteration of the digestive
system to control obesity cannot be considered the long-term
solution as there is nothing wrong with the gut in the first place:
in fact it could be argued that obesity is a consequence of a
super-efficient digestive system. The problem is in central
command: irrespective of whether the obesity is a conse-
quence of over-eating or low metabolic expenditure rates, the
condition can be cured by reduced eating, and negative
energy balance. Consequently, the optimal treatment and
prevention of obesity will have to be the development of new
more potent methods of suppressing appetite and controlling
food intake so that digestive physiology can be preserved to
prevent potentially serious nutritional-metabolic and surgical
complications. Until such time as this goal is achieved,
bariatric surgery will, however, remain the most effective way
of reducing the morbidity associated with extreme, class III
obesity. However, our results indicate the need for a vigilant
nutritional and metabolic follow up, even in patients who have
few symptoms to report. In those with intermittent diarrhea,
continued weight loss, or micronutrient deficiencies, a
therapeutic trial of pancreatic enzyme supplements could be
justified to counterbalance possible ileal brake driven
maldigestion.
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Study-Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Morbid obesity (BMI440 kg/m2) now affects approximately
35% of the USA population.
✓ The most effective current treatment is gastric bypass
surgery.
✓ Roux-en-Y gastric bypass surgery is effective principally
due to suppressed food consumption, but mild
malabsorption may also occur.
✓ Malabsorption is due to the shortened length of the
“common channel” of small intestine.
WHAT IS NEW HERE
✓ Some patients develop severe fat malabsorption, i.e.,
steatorrhea, following Roux-en-Y gastric bypass surgery for
obesity.
✓ Fat malabsorption was associated with suppressed
pancreatic enzyme secretory responses to feeding.
✓ The reduced pancreatic secretory responses to feeding
were associated with increased ileal brake peptide (GLP-1,
peptide-YY) responses.
✓ Pancreatic enzyme supplementation reduced steatorrhea
in some patients.
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